

# Antimicrobial Renal Dosage Adjustment Guidelines for Adults

[milligrams or grams/dosing interval in hours unless otherwise specified]

**Doses are for 70 kg adults; smaller or larger patients, or those receiving certain modes of renal replacement therapy may require additional dosage adjustments**  
*Some antimicrobials require dose adjustment in hepatic dysfunction. Please refer to specialized references for dosing considerations.*

Antimicrobial doses in chart represent usual initial adult doses for moderate to severe infections due to susceptible organisms. **Specific disease states or individual patients may warrant dosages that differ from the recommendations.** Please contact the pharmacist serving your patient care area for patient-specific recommendations.

|   |    | CREATININE CLEARANCE (mL/min)   |                                    |                                    |                               |                               |                              |
|---|----|---|------------------------------------|------------------------------------|-------------------------------|-------------------------------|------------------------------|
| Drug & Administration Route               |    | > 80  | 50-80                              | 30-50                              | 10-30                         | < 10/ hemodialysis            | CRRT                         |
| <b>PENICILLINS</b>                        |    |   |                                    |                                    |                               |                               |                              |
| Amoxicillin                               | po | 250-500mg/q8h or 875mg/q12h or 1gram/q8h  |                                    | 250-500mg/q8-12h                   |                               | 250-500mg/q24h                |                              |
| Amoxicillin/<br>clavulanate               | po | 500mg/q8h or 875mg/q12h   |                                    |                                    | 250-500mg/q12h                | 250-500mg/q24h                |                              |
| Ampicillin <sup>LOAD</sup>                | iv | 500mg-2gram/q4-6h<br>Endocarditis/meningitis: 2gram IV q4h  |                                    | 500mg-2gram/q8h                    | 500mg-2gram/ q12h             | 500mg-2gram/ q12-24h          | 1-2gram/q8h-q12h             |
| Ampicillin /<br>sulbactam <sup>LOAD</sup> | iv | 1.5-3gram/q6h   |                                    | 1.5-3gram/q6-8h                    | 1.5-3gram/q12h                | 1.5-3gram/q12h-24h            | 1.5-3gram/q8h                |
| Ampicillin /<br>sulbactam <sup>LOAD</sup> | iv | 4 hour infusion<br>9grams/q8h<br>Severe infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) OR combination therapy for infections caused by ampicillin/sulbactam non-susceptible CRAB                                       |                                    | 30 min infusion<br>3gram/q6h       | 30 min infusion<br>3gram/q8h  | 30 min infusion<br>3gram/q12h | 30 min infusion<br>3gram/q6h |
| Ampicillin /<br>sulbactam <sup>LOAD</sup> | iv | 30 min infusion<br>3gram/q4h<br>Infections caused by ampicillin/sulbactam susceptible <i>Acinetobacter baumannii</i> OR Endocarditis/endovascular infections OR Osteomyelitis OR renally dose adjusted HIGH DOSE extended infusion ampicillin/sulbactam |                                    | 3gram/q6h                          | 3gram/q8h                     | 3gram/q12h                    | 3gram/q6h                    |
| Dicloxacillin                             | po | 125-1000mg/q6h  | No adjustment in renal dysfunction |                                    |                               |                               |                              |
| Oxacillin                                 | iv | 1-2gram/q4h<br>OR continuous infusion 12gram/24hrs  |                                    | No adjustment in renal dysfunction |                               |                               |                              |
| Penicillin G<br>intermittent infusion     | iv | 2-4 mU/q4-6h  |                                    | 2-3 mU/q4-6h                       |                               | 2 mU/q6h                      | 2-4mU/q6h                    |
| Penicillin G<br>continuous infusion       | iv | 18-24mU/24hrs   | 18mU/24hrs                         | 15-18mU/24hrs                      | Use intermittent dosing above |                               |                              |

|   |    | CREATININE CLEARANCE (mL/min)  |               |                  |                            |   |  |   |
|---|----|--|---------------|------------------|----------------------------|---|--|---|
| Drug & Administration Route   |    | > 80   | 50-80         | 30-50            | 10-30                      | < 10/ hemodialysis  | CRRT   |   |
| Piperacillin /<br>tazobactam <sup>LOAD</sup><br>extended infusion     | iv | 4 hour infusion ( <b>preferred</b> when available)<br>3.375gram/q8h (adequate for <i>P aeruginosa</i> ) <sup>a</sup>   |               |                  | <20ml/min: 3.375gram/q12h  |   | 3.375gram/q8h <sup>c</sup>   |   |
|   |    | 4.5gram/q8h<br>Cystic Fibrosis <sup>b</sup> , BMI $\geq$ 40kg/m <sup>2</sup> , infection due to gram-neg bacteria MIC $\geq$ 16  |               |                  |                            |   | 4.5gram q8h <sup>c</sup>   |   |
| Piperacillin /<br>tazobactam <sup>LOAD</sup><br>intermittent infusion | iv | 30 min infusion<br>3.375gram/q6h   |               | 2.250gram/q6h    |                            | 2.250gram/q8h   | 2.250gram/q6h  |   |
|   |    | 4.5gram/q6h<br>Empiric Rx nosocomial infection, monotherapy for<br><i>P aeruginosa</i> , Cystic Fibrosis, BMI $\geq$ 40kg/m <sup>2</sup> ,<br>infection due to gram-neg bacteria MIC $\geq$ 16 |               | 3.375gram/q6h    | 2.250gram/q6h              |   |  |   |
| <b>CEPHALOSPORINS</b>   |    |  |               |                  |                            |   |  |   |
| Cefazolin   | iv | 1-2gram/q8h  |               |                  | 1-2gram/q12h               | 1gram/q24h<br>On stable tiw HD: 2gram<br>before 48hr dialytic intervals,<br>3gram before 72 hr dialytic<br>interval | 2gram/q12h   |   |
| Cephalexin  | po | 250-1gram/q6h  | 250-500mg/q8h | 250-500mg/q8-12h |                            | 250-500mg/q12-24h   |  |   |
| Cefdinir  | po | 300mg /q12h  |               |                  | 300mg /q24h                | 300mg after each HD   |  |   |
| Cefotetan   | iv | 1-2gram/q12h   |               |                  | 1-2gram/q24h               | 1-2gram /q48h   |  |   |
| Cefoxitin   | iv | 1-2gram/q6h  |               | 1-2gram/q8h      | 1-2gram/q12h               | 1-2gram/q24h  |  |   |
| Cefpodoxime   | po | 100-400mg/q12h   |               |                  | 100-400mg/ q24h            | 100-400mg/tiw <sup>6</sup>  |  |   |
| Ceftaroline   | iv | 600mg/q12h<br>Standard dose  |               | 400mg/q12h       | 15-30ml/min:<br>300mg/q12h | <15ml/min:<br>200mg/q12h  | Sparse data:<br>Consider 300-400mg/q12h<br>depending on effluent flow rate, patient<br>weight, and organism MIC. Every 8 hour<br>dosing may be appropriate if treating deep-<br>seated MRSA infection <sup>5</sup> |   |
|   |    | 600mg/q8h<br>MRSA bacteremia, systemic infection <sup>p</sup>  |               | 400mg/q8h        | 300mg/q8h                  | 200mg/q8h   |  |   |
| Cefuroxime  | po | 250-500mg/q12h   |               |                  |                            | 250-500mg/q12-24h   |  |   |
| Cefuroxime <sup>LOAD</sup>  | iv | 750mg-1.5gram/q8h  |               |                  | 750mg/q12h                 | 750mg/q24h  |  |   |
| Cefotaxime <sup>LOAD</sup>  | iv | 1-2gram/q6-8h  | 1-2gram /q8h  | 1-2gram/q8-12h   | 1-2gram/q12h               | 1-2gram/q24h  | 1-2gram/q12h   |   |
| Ceftazidime <sup>LOAD</sup><br>extended infusion                      | iv | 4 hour infusion<br>1gram/q8h<br>Hospital acquired pneumonia, bloodstream infection,<br>urinary tract infection, intra-abd infection,<br>sepsis other source                                    |               | 1gram/q12h       | 1gram/q24h                 | 500mg/q24h  |  |   |
|   |    | 2gram/q8h<br>Osteomyelitis, CNS infection /meningitis , neutropenic<br>fever, endocarditis, cystic fibrosis exacerbation,<br>Gram neg orgs with MIC $\geq$ 4 mcg/mL                            |               | 1gram/q8h        | 1gram/q12h                 | 1gram/q24h  |  |   |
| Ceftazidime-<br>avibactam <sup>LOAD</sup>                             | iv | 2.5gram/q8h  |               | 1.25gram/q8h     | 16-30mL/min<br>940mg/q12h  | 6-15mL/min<br>940mg/q24h  | <6mL/min or<br>HD<br>940mg/q48h  | Sparse data<br>Consider 1.25gram/q8h <sup>d</sup> |

|  |    | CREATININE CLEARANCE (mL/min)  |                          |                                    |  |  |  |
|--|----|--|--------------------------|------------------------------------|--|--|--|
| Drug & Administration Route  |    | > 80   | 50-80                    | 30-50                              | 10-30  | < 10/ hemodialysis   | CRRT   |
| Ceftolozane-tazobactam <sup>LOAD</sup>   | iv | 1.5gram/q8h  |                          | 750mg/q8h                          | 15-29mL/min<br>375mg/q8h                     | <15mL/min or HD<br>750mg load, then<br>150mg/q8h                     | 750mg-1.5gram/q8h <sup>e</sup>   |
|  |    | 3gram/q8h <sup>f</sup><br>Hospital acquired pneumonia  |                          | 1.5gram/q8h                        | 750mg/q8h                                    | 2.25gram x1 then<br>450mg/q8h  |  |
| Ceftriaxone  | iv | 1-2gram/q24h   |                          | No adjustment in renal dysfunction |  |  |  |
|  |    | 2gram/q12h<br>CNS infection; Enterococcal endocarditis with ampicillin   |                          | No adjustment in renal dysfunction |  |  |  |
| Cefepime <sup>LOAD</sup><br>extended infusion  | iv | <u>4 hour infusion</u><br>1gram/q8h<br>Health-care pneumonia, GNR Bloodstream infection, urinary tract infection, intra-abd infection, sepsis other source |                          | 1gram/q12h                         | 1gram/q24h                                   | 500mg/q24h<br>On stable tiw HD:2grams after HD                       | 1gram/q8h <sup>g</sup>   |
|  |    | 2gram/q8h<br>Osteomyelitis, CNS infection /meningitis , neutropenic fever, endocarditis, cystic fibrosis exacerbation, Gram neg orgs with MIC≥4 mcg/mL     |                          | 1gram /q8h                         | 1gram/q12h                                   | 1gram/q24h<br>On stable tiw HD: 2grams after HD                      |  |
| Cefiderocol  | iv | 2gram/ q8h<br>(2gram/q6h if CrCl> 120mL/min)   |                          | 30-59 mL/min<br>1.5 gram/ q8h      | 15-29mL/min<br>1 gram/q8h                    | <15mL/min or HD<br>0.75gram/q12h                                     | <u>Effluent flow rate</u> <sup>*</sup> <u>Dose</u><br>2L/hr or less     1.5gram/ q12h<br>2.1 – 3.0L/hr     2 gram/ q12h<br>3.1 – 4 L/hr     1.5gram/ q8h<br>≥4.1L/hr     2 gram/ q8h |
| *Ultrafiltrate flow rate for CVVH, dialysis flow rate for CVVHD, ultrafiltrate flow rate plus dialysis flow rate for CVVHDF. |    |  |                          |                                    |  |  |  |
| <b>CARBAPENEMS</b>   |    |  |                          |                                    |  |  |  |
| Meropenem <sup>LOAD</sup><br>extended infusion   | iv | <u>3 hour infusion</u><br>1gram/q8h  |                          | 500mg/q8h                          | 500mg/q12h                                   | 500mg/q24h   | 500mg-1gram/q8h <sup>h</sup><br>Higher dose in acute kidney injury and/or in patients with preserved diuresis  |
|  |    | 2gram/q8h<br>Meningitis, cystic fibrosis exacerbation  |                          | 1gram/q8h                          | 1gram/q12h                                   | 500mg/q12h   | 1gram/q8h <sup>h</sup>   |
| Ertapenem  | iv | 1gram/q24h   |                          |                                    | 500mg/q24h                                   | On stable tiw HD: 500mg -<br>1gram after each HD <sup>g</sup>        | 1gram/q24h <sup>i</sup>  |
| Imipenem/<br>Cilastatin  | iv | >90mL/min<br>500mg q6h OR<br>1gram/q8h<br>Susceptible bacteria   | 60-90mL/min<br>500mg/q6h | 30-60mL/min<br>500mg/q8h           | 15-30mL/min<br>500mg/q12h                    | Do not give unless<br>renal replacement<br>is in place<br>500mg/q12h | 500mg/q8h  |
|  |    | 1gram/q6h<br>Intermediately<br>susceptible bacteria  | 750mg/q8h                | 500mg/q6h                          |  |  | 500mg/q6-8h  |
| Meropenem/<br>Vaborbactam<br>Dose adjustments using GFR  |    | 4gram/q8h<br>2gram meropenem, 2gram vaborbactam/dose   |                          | 2gram/q8h                          | 15-29mL/min/1.73m <sup>3</sup><br>2gram/q12h | <15mL/min/1.73m <sup>3</sup><br>1gram/q12h                           | 2gram/q8h  |

| Drug & Administration Route           | CREATININE CLEARANCE (mL/min)   |                                 |                                    |                                  |   |  |
|---------------------------------------|---|---------------------------------|------------------------------------|----------------------------------|---|--|
|                                       | > 80  | 50-80                           | 30-50                              | 10-30                            | < 10/ hemodialysis  | CRRT                                       |
| <b>Other Beta-Lactams</b>             |   |                                 |                                    |                                  |   |  |
| Aztreonam <sup>LOAD</sup> iv          | 1-2gram/q6-8h<br>Use q6h in febrile neutropenia   |                                 | 1-2gram/q8h                        | 1gram/q8h or<br>2gram/q12h       | 500mg-1gram/q12h  | 2gram/q12h                                 |
| Sulbactam/<br>Durlobactam iv          | >130ml/min<br>1gram/1gram/q4h   | 45-129ml/min<br>1gram/1gram/q6h | 30-44ml/min<br>1gram/1gram/q8h     | 15-29 ml/min<br>1gram/1gram/q12h | <15ml/min or HD<br>1gram/1gram/q24h<br>New starts give q12h x3<br>doses before adjusting to<br>q24h | Sparse data:<br>Consider 1gram/1gram/q8h   |
| <b>FLUOROQUINOLONES</b>               |   |                                 |                                    |                                  |   |  |
| Ciprofloxacin<br><u>low dose</u> po   | 250mg/q12h<br>Uncomplicated urinary tract infection   |                                 | 250mg/q12h                         | 250mg/q24h                       |   | Sparse data:<br>Consider 250 to 750mg/q12h |
| <u>mid-dose</u>                       | 500mg/q12h<br>Complicated UTI, intraabdominal infection, prostatitis, sinusitis                             |                                 | 500mg/q12h                         | 500mg/q24h                       |   |  |
| <u>high dose</u>                      | 750mg/q12h<br>Severe /nosocomial pneumonia, bone/joint infection, bacteremia                                |                                 | 500mg/q12h                         | 750mg/q24h                       |   |  |
| Ciprofloxacin<br><u>low dose</u> iv   | 200mg/q12h<br>Uncomplicated urinary tract infection   |                                 | 200mg/q12h                         | 200mg/q24h                       |   | 200mg/q24h                                 |
| <u>mid-dose</u>                       | 400mg/q12h<br>Complicated UTI, intraabdominal infection, prostatitis, sinusitis                             |                                 | 400mg/q24h                         | 200mg/q12h or 400mg/q24h         |   | 400mg/q24h                                 |
| <u>high dose</u>                      | 400mg/q8h<br>Severe /nosocomial pneumonia, bone/joint infection, bacteremia, serious Pseudomonal infections |                                 | 400mg/q12h                         | 200mg/q12h or 400mg/q24h         |   | 400mg/q12h                                 |
| Levofloxacin<br><u>low dose</u> iv/po | 250mg/q24h<br>Uncomplicated urinary tract infection   |                                 | 20-49mL/min<br>250mg/q24h          |                                  | <20mL/min, HD/PD<br>250mg/q24h  | 250mg/q24h                                 |
| <u>mid-dose</u>                       | 500mg/q24h<br>Prostatitis, sinusitis  |                                 | 500mg x 1 then 250mg/q24h          |                                  | 500mg x1 then<br>250mg/q48h   | 500mg x 1 then 250mg/q24h                  |
| <u>high dose</u>                      | 750mg/q24h<br>Pneumonia, complicated UTI, pyelonephritis, bacteremia  |                                 | 750mg/q48h                         |                                  | 750mg x 1, then<br>500mg/q48h   | 750mg x 1, then 500mg/q24h                 |
| Moxifloxacin po/iv                    | 400mg/q24h  |                                 | No adjustment in renal dysfunction |                                  |   |  |

| Drug & Administration Route  | CREATININE CLEARANCE (mL/min)   |   |   |       |                    |      |
|--|---|---|---|-------|--------------------|------|
|  | > 80  | 50-80   | 30-50   | 10-30 | < 10/ hemodialysis | CRRT |
| <b>MISCELLANEOUS ANTIMICROBIALS</b>  |   |   |   |       |                    |      |
| Amikacin   | See separate chart  |   |   |       |                    |      |
| Azithromycin po/iv   | 250-500mg/q24h  | No adjustment in renal dysfunction  |   |       |                    |      |
| Clarithromycin po  | 250-500mg/q12h  | 125-250mg/q12 or 250-500mg/q24h   |   |       |                    |      |
| Clindamycin po   | 150-450mg/q6-8h   | No adjustment in renal dysfunction  |   |       |                    |      |
| Clindamycin iv   | 600-900mg/q8h   |   |   |       |                    |      |
| Colistimethate <sup>j</sup> LOAD<br>Dose expressed in mg colistin base activity<br>Load:300mg, begin maint dose 12 hrs later | >90mL/min 180mg q12h<br>80 - <90mL/min 170mg q12h<br>70 - <80mL/min 150mg q12h<br>60 - <70mL/min 140mg q12h<br>50 - <60mL/min 125mg q12h  | 40 - <50mL/min 110mg q12h<br>30 - <40mL/min 98mg q12h<br>20 - <30mL/min 88mg q12h<br>10- <20mL/min 80mg q12h<br>5 - <10mL/min 75mg q12h   | After 3hr HD: 170mg x1<br>After 4hr HD: 180mg x1<br>Non-HD days: 130mg x1 |       | 220mg q12h         |      |
| Dapsone po   | 100mg/q24h  | 50mg/q24h   |   |       |                    |      |
| Daptomycin iv<br>Use AdjBW if obese<br>Dose is organism and MIC dependent  | 4mg/kg/q24h<br>Cystitis<br>6mg/kg/q24h<br>Severe SSTI, blood stream infection, osteomyelitis, prosthetic joint infxn, septic arthritis, endocarditis<br>≥8mg/kg/q24h<br>Infection due to <i>E faecium</i> or any vancomycin-resistant Enterococci, consider alternate agent if Enterococcus MIC≥4mcg/mL | 4mg/kg/q48h<br>6-8mg/kg/q48h<br>On stable tiw HD: 6mg/kg before 48hr dialytic intervals, 9mg/kg before 72 hr dialytic interval<br>Sparse data for dose adjustments of doses >8mg/kg:<br>Consider ≥8mg/kg/q48h or seek guidance regarding dose adjustment (CAUSE, clinical pharmacist, ID clinician) | 6-8mg/kg/q24h <sup>k</sup><br>Consider ≥8mg/kg q24h if VRE                |       |                    |      |
| Dalbavancin iv   | 1500mg x1<br>SSTI<br>1500mg x1, repeat day 8<br>Osteomyelitis   | 1125mg x 1 if not on hemodialysis.<br>no adjustment required if on hemodialysis<br>1000mg x1, repeat day 8 <sup>l</sup>   |   |       |                    |      |
| Doxycycline po/iv  | 100mg/q12h  | No adjustment in renal dysfunction  |   |       |                    |      |
| Minocycline po/iv  | 100mg/q12h<br>200mg/q12h<br>Multidrug-resistant gram-negative infections (eg, carbapenem-resistant <i>Acinetobacter</i> sp., <i>S. maltophilia</i> ) and nocardiosis,   | No adjustment in renal dysfunction  |   |       |                    |      |
| Gentamicin   | See separate chart  |   |   |       |                    |      |
| Linezolid po/iv  | 600mg/q12h  | No adjustment in renal dysfunction  |   |       |                    |      |
| Metronidazole po/iv  | 500mg/q8-12h<br>500mg/q6h<br>CNS infections   | No adjustment necessary   |   |       |                    |      |
| Fidaxomicin po   | 200mg BID x 10 days   | No adjustment in renal dysfunction  |   |       |                    |      |

|                             |  | CREATININE CLEARANCE (mL/min)  |       |  |                                    |                               |                              |
|-----------------------------|--|--|-------|--|------------------------------------|-------------------------------|------------------------------|
| Drug & Administration Route |  | > 80   | 50-80 | 30-50  | 10-30                              | < 10/ hemodialysis            | CRRT                         |
| Fosfomycin                  | po   | 3grams x 1<br>Uncomplicated cystitis only  |       | No adjustment in renal dysfunction                   |                                    |                               |                              |
| Nitrofurantoin              | po   | 100mg/q12h<br>Dose depends on formulation, doses based off Macrobid formulation  |       | 30-60mL/min<br>no dose adjustment for short term use | Not effective, avoid use           |                               |                              |
| Pentamidine                 | iv   | 3-4mg/kg/q24h  |       |  | 3-4mg/kg/q24-36h                   | 3-4mg/kg/q48h                 |                              |
| Tigecycline                 | iv   | 100mg x 1 then 50mg/q12h   |       |  | No adjustment in renal dysfunction |                               |                              |
|                             |  | 200mg x 1 then 100mg/q12h<br>Multidrug-resistant gram-negative infections (eg <i>S. maltophilia</i> , <i>Acinetobacter baumannii</i> ) |       |  |                                    |                               |                              |
| TMP/SMX                     | po/iv<br>Dosed on mg of trimethoprim component<br><br>If obese, consider dosing on AdjBW | 160mg (1 DS tablet)/q12h<br>Urinary tract infection  |       |  | 160mg/q24h                         | 160mg/q48h                    |                              |
|                             |  | 320mg (2 DS tablets)/q12h<br>Community-acquired MRSA soft tissue infection   |       |  | 160mg/q12h                         | 160mg/q24h                    |                              |
|                             |  | 8-12mg/kg/day divided q6-8h<br><i>S. maltophilia</i>   |       |  | 4-6mg/kg/day divided q8-12h        | 2-3mg/kg/day divided q12-24h  | 8-12mg/kg/day, divided q6-8h |
|                             |  | 10-15mg/kg/day divided q6-8h<br><i>Nocardia spp.</i>   |       |  | 7-12mg/kg/day divided q8-12h       | 5-7mg/kg/day divided q12-24h  |                              |
|                             |  | 10mg/kg/day divided q12h<br>Toxoplasma encephalitis  |       |  | 5mg/kg/day divided q12h            | 2.5mg/kg/q24h                 | 10mg/kg/day, divided q12h    |
|                             |  | 15mg/kg/day divided q6h<br><i>Pneumocystis jiroveci (carinii)</i> Pneumonia  |       |  | 7.5-12mg/kg/day divided q6-8h      | 4-7.5mg/kg/day divided q8-12h | 15mg/kg/day, divided q6-8h   |
| Tobramycin                  |  | See separate chart   |       |  |                                    |                               |                              |
| Vancomycin                  |  | See separate chart   |       |  |                                    |                               |                              |

| Drug & Administration Route   | CREATININE CLEARANCE (mL/min)   |       |                           |  |  |               |
|---|---|-------|---------------------------|--|--|---------------|
|   | > 80  | 50-80 | 30-50                     | 10-30  | < 10/ hemodialysis                         | CRRT          |
| <b>ANTIVIRALS</b>   |   |       |                           |  |  |               |
| Acyclovir<br>iv<br>If obese, consider dosing on AdjBW to avoid underdosing <sup>m</sup> | 5mg/kg/q8h<br>HSV treatment   |       | 5mg/kg/q12h               | 5mg/kg/q24h  | 2.5mg/kg/q24h                              | 5mg/kg/q24h   |
|   | 10mg/kg/q8h<br>HSV encephalitis, VZV treatment  |       | 10mg/kg/q12h              | 10mg/kg/q24h   | 5mg/kg/q24h                                | 7.5mg/kg/q24h |
|   | 100mg/q12h<br>Prophylaxis all indications   |       |                           | 100mg/q24h   |  | 100mg/q12h    |
| Acyclovir<br>po   | 400mg/q8h<br>HSV treatment  |       |                           | 400mg/q12h   | 400mg/q24h                                 |               |
|   | 800mg 5x daily<br>VZV treatment   |       |                           | 800mg/q8h  | 800mg BID                                  |               |
|   | 400mg/q12h<br>Prophylaxis in immunocompromised patients (eg HIV, SOT, chemotherapy)     |       |                           | 400mg/q24h   |  |               |
|   | 400mg/q8h<br>Prophylaxis in stem cell transplant (SCT)                                  |       | 400mg/q12h                | 400mg/q24h   |  |               |
|   | 800mg/q12h<br>VZV prophylaxis after SCT or bortezomib                                   |       |                           | 800mg/q24h   |  |               |
| ValACYclovir<br>po  | 1gram/q12h x 10days<br>Genital HSV – initial episode treatment                          |       |                           | 1gram/q24h   | 500mg/q24h                                 |               |
|   | 1gram/q24h x 5 days, or 500mg/q12h x 3days<br>Genital HSV – recurrent episode treatment |       |                           | 1gram/q48h x 3 doses or 500mg/q24h x 3 days                          |  |               |
|   | 1000mg/q12h x 5-10 days<br>HIV + and Genital HSV – recurrent episode treatment          |       |                           | 1000mg/q24h x 5-10 days  |  |               |
|   | 500mg/q12h<br>Genital HSV suppression – HIV+ or >10 recurrences /year                   |       |                           | 500mg/q24h   |  |               |
|   | 1gram/q8h<br>VZV treatment  |       | 1gram/q12h                | 1gram/q24h   | 500mg/q24h                                 |               |
| Tenofovir disoproxil fumarate<br>po   | 300mg/q24h  |       | 300mg/q48h                | 300mg/q72-96h  | 300mg/q7days or after ~ 12hrs hemodialysis |               |
| Tenofovir alafenamide<br>po   | 25mg/q24h   |       |                           | CrCl<15mL/min and not on HD: Not recommended, assess risk vs benefit | 25mg/q24h                                  |               |
| Entecavir<br>po   | 0.5mg/q24h<br>Standard dose   |       | 0.25mg/q24h OR 0.5mg/q48h | 0.15mg/q24h OR 0.5mg/q72hrs  | 0.05mg/q24h OR 0.5mg/q7days                |               |
|   | 1mg/q24h<br>decompensated liver disease OR HBV refractory-to-lamivudine                 |       | 0.5mg/q24h OR 1mg /q48h   | 0.3mg/q24h OR 1mg/q72hrs   | 0.1mg/q24h OR 1mg/q7days                   |               |

| Drug & Administration Route                                       | CREATININE CLEARANCE (mL/min)  |                              |   |  |                                  |                        |
|---|--|------------------------------|---|--|----------------------------------|------------------------|
|   | > 80   | 50-80                        | 30-50   | 10-30  | < 10/ hemodialysis               | CRRT                   |
| Tenofovir disoproxil fumarate 300mg/<br>emtricitabine 200mg<br>po | 1 tablet/q24h  |                              | 1 tablet/q48h   |  |                                  |                        |
| Tenofovir alafenamide 25mg/emtricitabine 200mg<br>po              | 1 tablet/q24h  |                              |   | CrCl<30mL/min and not on HD: Not recommended, assess risk vs benefit | 1 tablet/q24h                    |                        |
| Foscarnet<br>iv   | 60mg/kg/q8h or 90mg/kg/q12h<br>CMV induction<br>-----<br>90-120mg/kg q24h<br>CMV maintenance   |                              | Adjustment required for CrCl ≤ 100 mL/min: To avoid toxicity, this medication requires careful dose adjustment based on nature of infection, body size, and renal function. Please seek guidance regarding dose adjustment (clinical pharmacist/ manufacturer's labeling) |  |                                  |                        |
| Ganciclovir <sup>LOAD</sup><br>iv                                 | ≥70mL/min<br>5mg/kg/q12h for 2-3 weeks<br>CMV induction  | 50-69mL/min<br>2.5mg/kg/q12h | 25-49mL/min<br>2.5mg/kg/q24h  | 10-24mL/min<br>1.25mg/kg/q24h  | 1.25mg/kg/3x weekly              | 2.5mg/kg/q12h          |
|   | ≥70mL/min<br>5mg/kg/q24h<br>CMV maintenance  | 50-69mL/min<br>2.5mg/kg/q24h | 25-49mL/min<br>1.25mg/kg/q24h   | 10-24mL/min<br>0.625mg/kg/q24h                                       | 0.625mg/kg/3x weekly             | 2.5mg/kg/q24h          |
| ValGANCiclovir<br>po  | ≥60mL/min<br>900mg/q12h<br>CMV induction   | 40-59mL/min<br>450mg/q12h    | 25-39mL/min<br>450mg/q24h   | 10-24mL/min<br>450mg/q2days  | 450mg after every other dialysis |                        |
|   | ≥60mL/min<br>900mg/q24h<br>CMV maintenance, prevention   | 40-59mL/min<br>450mg/q24h    | 25-39mL/min<br>450mg/q2days   | 10-24mL/min<br>450mg/twice weekly                                    |                                  |                        |
| Maribavir<br>po   | 400mg q12h   |                              | No adjustment in renal dysfunction  |  |                                  |                        |
| Lamivudine<br>po  | 100mg/q24h<br>HBV treatment  |                              | 50-100mg/q24h   |  |                                  |                        |
| Remdesivir<br>iv  | 200mg IV x 1, then 100mg/q24h  |                              |   | No dose adjustment   |                                  |                        |
| Ribavirin<br>po   | Dose modification required for GFR≤80mL/min. To avoid toxicity, this medication requires careful dose adjustment based on viral infection being treated (HCV, RSV, others), body size, and renal function. Please seek guidance regarding dose adjustment (CAUSE pager, clinical pharmacist, ID clinician) |                              |   |  |                                  |                        |
| Oseltamivir<br>po   | >60mL/min<br>75mg/q12h<br>Influenza treatment  | 30-60mL/min<br>30mg/q12h     |   | 30mg/q24h  | 30mg after every HD              | 75mg/q24h <sup>n</sup> |
|   | >60mL/min<br>75mg/q24h<br>Influenza prevention   | 30-60mL/min<br>30mg/q24h     |   | 30mg/q48h  | 30mg after alternate HD          | 75mg/q48h              |



| Drug & Administration Route   |       | CREATININE CLEARANCE (mL/min)   |                                    |                             |  |   | CRRT  |
|---|-------|---|------------------------------------|-----------------------------|--|---|---|
|   |       | > 80  | 50-80                              | 30-50                       | 10-30  | < 10/ hemodialysis  |   |
| <b>ANTIMYCOBACTERIALS</b>   |       |   |                                    |                             |  |   |   |
| Ethambutol<br>Use IBW if obese <sup>o</sup>   | po    | 15-25mg/kg/q24h (max dose/day = 2000mg)   |                                    |                             | 15-25mg/kg tiw<br>(after dialysis if on hemodialysis) <sup>o</sup> |   |   |
| Isoniazid   | po    | 300mg/q24h  | No adjustment in renal dysfunction |                             |  |   |   |
| Rifabutin   | po    | 300mg/q24h  |                                    |                             | Reduce dose by 50% if toxicity is suspected                        |   |   |
| Rifampin  | po/iv | 600mg/q24h  | No adjustment in renal dysfunction |                             |  |   |   |
| Pyrazinamide<br>Use IBW if obese <sup>o</sup>   | po    | 25-35mg/kg/q24h (max dose/day = 3000mg)   |                                    |                             | 25-35mg/kg tiw<br>(after dialysis if on hemodialysis) <sup>o</sup> |   |   |
| <b>ANTIFUNGALS</b> §: serum concentration monitoring may be useful for optimizing therapy |       |   |                                    |                             |  |   |   |
| Amphotericin B deoxycholate (Conventional)  | iv    | 0.25-1.5mg/kg/q24h, no adjustment in renal dysfunction  |                                    |                             |  |   |   |
| Liposomal Amphotericin B  | iv    | 3 or 5mg/kg/q24h, no adjustment in renal dysfunction  |                                    |                             |  |   |   |
| Fluconazole <sup>LOAD</sup>   | iv/po | Full indicated dose or greater: 400-800mg/q24h<br>Doses of 1200mg/day have been reported  |                                    |                             | 50% of full dose/q24h<br>give after HD in pts on HD                |   | Full indicated dose or greater:<br>400-800mg/q24h |
|   |       | 6-12mg/kg q24h (400-800mg/dose)<br>High intensity dose for serious infections   |                                    |                             |  |   |   |
| Flucytosine §   | po    | 25mg/kg/q6h   | 40-50 mL/min<br>25mg/kg/ q6-8h     | 20-40mL/min<br>25mg/kg q12h | 10-19 mL/min<br>25mg/kg /q24h                                      | <10mL/min<br>25mg/kg/q48h<br>Hemodialysis<br>25-50mg/kg post HD | 25mg/kg/q8h                                       |
| Isavuconazonium <sup>LD</sup>   | iv/po | 372mg/q8h x 6 doses, then 372mg/q24h, No adjustment in renal dysfunction  |                                    |                             |  |   |   |
| Itraconazole <sup>LOAD</sup> §  | po    | 200mg/q8-24h<br>Dose varies by indication and dosage form used<br>Loading dose may be indicated based on treatment indication       |                                    |                             | No adjustment in renal dysfunction                                 |   |   |
| Micafungin  | iv    | 100mg/q24h<br>Candidemia, disseminated candidiasis, peritonitis, abscess  |                                    |                             |  |   | No adjustment in renal dysfunction                |
|   |       | 150mg/q24h<br>Esophageal or other mucocutaneous candidiasis, endocarditis, invasive aspergillosis, >100kg, BMI >40kg/m <sup>2</sup> |                                    |                             |  |   |   |
|   |       | 50mg/q24h<br>Fungal prophylaxis in immunocompromised patient  |                                    |                             |  |   | CRRT: 100-150mg/q24h <sup>f</sup>                 |

| Drug & Administration Route   | CREATININE CLEARANCE (mL/min)  |       |                                    |   |                                    |      |
|---|--|-------|------------------------------------|---|------------------------------------|------|
|   | > 80   | 50-80 | 30-50                              | 10-30   | < 10/ hemodialysis                 | CRRT |
| Rezafungin <sup>LOAD</sup> iv   | 400 mg x 1 on day 1, then 200 mg once weekly beginning on day 8 for up to 4 doses<br>Candidemia and invasive candidiasis |       |                                    |   | No adjustment in renal dysfunction |      |
| Posaconazole <sup>LOAD</sup> §<br>po/iv   | 300mg/q12h x 2 doses, then 300mg/q24h  |       |                                    | No adjustment in renal dysfunction. Use tablets for oral dosing, suspension exhibits variable absorption. |                                    |      |
| Voriconazole <sup>LOAD</sup> §<br>po/iv<br>Use IBW if obese   | 6mg/kg/q12h x 2 doses<br>Loading dose  |       | No adjustment in renal dysfunction |   |                                    |      |
|   | 4mg/kg/q12h x 1 week<br>Induction dose   |       |                                    |   |                                    |      |
|   | 200mg/q12h<br>Maintenance dose   |       |                                    |   |                                    |      |
| <b>Antiretrovirals: See Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, <a href="https://clinicalinfo.hiv.gov/en/guidelines">https://clinicalinfo.hiv.gov/en/guidelines</a>, Appendix B, Table 7. Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency</b> |  |       |                                    |   |                                    |      |

#### ABBREVIATIONS

LOAD: Consider larger initial "loading" dose when renal function is poor. TMP-SMX = trimethoprim-sulfamethoxazole; MRSA: Methicillin resistant *Staphylococcus aureus*, CA-MRSA: Community acquired methicillin resistant *Staphylococcus aureus*, mU = million units, tiw = 3 times weekly; 5x/d =5 times a day, biw = twice weekly,

CRRT= Continuous Renal Replacement Therapy, continuous veno-venous hemofiltration, etc. Many variables are involved in CRRT drug removal. Doses shown are suggested by the literature reporting a limited number of patients being studied in a variety of CRRT settings. Clinical judgement should be exercised when individualizing doses, taking into account severity of infection, residual renal function, acuity /chronicity of kidney injury, etc. [Trotman, et al. Clin Infect Dis;41:1159, Heintz, et al Pharmacotherapy 2009;29:562, Hoff, et al Ann Pharmacother 2019].

#### REFERENCES

- |  |  |
|--|--|
| <p>a. Lodise TP, et al. Clin Infect Dis 2007; 44:357, Kim A. et al. Pharmacother, 2007, 27:1490</p> <p>b. Bulitta, et al. Antimicrob Agents Chemother 2007; 51:2497; Butterfield et al, J Antimicrob Chemother 2014; 69:176</p> <p>c. Asin-Prieto, et al J Antimicrob Chemother 2014;69:180; Shotwell, et al. Clin J Am Soc Nephrol 2016;11:1377</p> <p>d. Wenzler, et al Antimicrob Agents Chemother 2018;61:e00464, Rivard, IDWEEK 2016, poster 2046</p> <p>e. Chajamorn, et al. Blood Purif 2017;44:16-23, Bremmer, et al. Pharmacotherapy 2016;36:e30-33, Oliver, et al. AAC 2015;60:1899</p> <p>f. Xiao, et al. J Clin Pharmacol 2016;56:56-66, Zerbaxa PI 2019</p> <p>g. Wilson, et al. Antimicrob Agents Chemother 2012;56:2178, Philpott, et al. Pharmacotherapy 2019</p> <p>h. Ulldemolins, et al Antimicrob Agents Chemother 2015;59:5520, Bilgrami, et al. Antimicrob Agents Chemother 2010;54:2974</p> <p>i. Eyler, et al Pharmacotherapy 2012;32:1061</p> <p>j. Tsuji, et al Pharmacotherapy 2019;39.</p> | <p>k. Xu, et al. Br J Clin Pharmacol 2017;83:498</p> <p>l. Rappo, et al. Open Forum Infect Dis 2018;10:ofy331</p> <p>m. Turner, et al. Antimicrob Agents Chemother 2016;60:1830</p> <p>n. Eyler, et al. Antimicrob Agents Chemother 2014;58:1320</p> <p>o. Nahid, et al. Clin Infect Dis 2016;63:e147-95</p> <p>p. Cosimi, et al. Open Forum Infect Dis 2017;4:ofx084</p> <p>q. Ueng, et al Antimicrob Agents Chemother 2019;63:e01427, Hsaiky, et al. Nephrol Dial Transplant 2019;34:1766</p> <p>r. Vussen et al. Antimicrob Agents Chemother 2017;61:1-9, Honore, et al. Crit Care 2018;22:289</p> <p>s. Kalaria, et al. Pharmacotherapy 2021</p> |
|--|--|

#### Creatinine Clearance Calculation - Adult Patients (Modified Cockcroft & Gault equation, displays in Encompass)

$$\text{CrCl (male)} = \frac{(140 - \text{age}) \times (\text{AdjBW}^* \text{ or } \text{TBW}^*)}{\text{SCr} \times 72}$$

\*whichever weight is lower

$$\text{CrCl (female)} = (\text{CrCl male}) \times (0.85)$$

SCr= Serum creatinine concentration in mg/dL

Equation may overestimate renal function in patients with decreased muscle mass

#### Weight-based dosing – Adult Patients (these weights visible in Encompass by "hovering" pointer over Weights box on lefthand column of inpatient screen)

- **TBW** = Total Body Weight in kilograms (kg)
- **IBW** = Ideal Body Weight in kilograms (kg) (an estimate of lean body weight)  
 $\text{IBW (male)} = 50\text{kg} + (2.3 \times \# \text{ inches height over } 5')$   
 $\text{IBW (female)} = 45.5\text{kg} + (2.3 \times \# \text{ inches height over } 5')$
- **AdjBW** = Adjusted Body Weight: for use in dosing selected drugs in obese patients, and in CrCL estimate  
 $\text{AdjBW} = ((\text{TBW} - \text{IBW}) \times 0.4) + \text{IBW}$